|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 52,600.00 ARS | -1.64% |
|
+2.68% | +12.25% |
| 07-28 | Atea Pharmaceuticals Says Combination Drug Meets Endpoints in Phase 3 Hepatitis C Trial | MT |
| 07-28 | Barclays Adjusts Gilead Sciences Price Target to $145 From $155, Maintains Equalweight Rating | MT |
Evolution of the Average Target: Gilead Sciences, Inc.
Evolution of the Target Price: Gilead Sciences, Inc.
Changes in Analyst Recommendations: Gilead Sciences, Inc.
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | ||
| +4.61% | |||||
| +1.45% | |||||
| +2.08% | |||||
| -1.08% | |||||
| -3.49% | |||||
| +22.78% | |||||
| -5.43% | |||||
| -9.17% | |||||
| +13.86% | |||||
| Average | +2.84% | |||||
| Weighted average by Cap. | +2.80% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| Barclays | |
| Leerink Partners | |
| Morgan Stanley | |
| Truist Securities | |
| RBC Capital Markets | |
| HSBC | |
| Maxim | |
| Daiwa Securities | |
| Rothschild & Co Redburn | |
| Goldman Sachs | |
| Cantor Fitzgerald | |
| Citigroup | |
| Argus | |
| Mizuho Securities | |
| Wolfe Research | |
| TD Cowen | |
| Deutsche Bank Securities | |
| Baird | |
| Scotiabank | |
| Bernstein | |
| BMO Capital | |
| Needham & Co. | |
| Oppenheimer | |
| JPMorgan Chase | |
| Wells Fargo Securities | |
| UBS | |
| DBS Bank | |
| BofA Securities | |
| Jefferies & Co. | |
| Redburn Atlantic | |
| Piper Sandler | |
| Raymond James | |
| SVB Securities LLC | |
| Cowen | |
| SVB Leerink | |
| Credit Suisse | |
| Redburn | |
| DZ BANK | Elmar Kraus |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GILD Stock
- GILD Stock
- Consensus Gilead Sciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
